Orange_Vol1321
Well-Known Member
- Joined
- Dec 4, 2012
- Messages
- 28,283
- Likes
- 42,514
Fauci on April 29, 2020 saying Remedisivir was safe and effective against Covid. The only thing that even shows that to be true was China saying they tried it on one patient and it helped them.
https://www.google.com/amp/s/www.cn...navirus-drug-trial-shows-quite-good-news.html
"This will be the standard of care," Fauci, director of the National Institute of Allergy and Infectious Diseases, added. "When you know a drug works, you have to let people in the placebo group know so they can take it."
Remedisivir was tried in 2018-19 for ebola. It was pulled 6 months early after 50% using it died. He knew it wasn't safe.
Two drugs reduce risk of death from Ebola
After results from the first 499 participants had been reviewed, the trial’s safety monitors recommended that two drugs—ZMapp and remdesivir—be dropped from the remainder of the trial. These two drugs were much less effective at preventing death.
Overall, about 50% of people who received either Zmapp or remdesivir died during the trial. In contrast, only about 35% of people who received either Mab114 or REGN-EB3 died. Three participants died of side effects thought to be related to treatment—two in the ZMapp group and one in the remdesivir group.
https://www.google.com/amp/s/www.cn...navirus-drug-trial-shows-quite-good-news.html
"This will be the standard of care," Fauci, director of the National Institute of Allergy and Infectious Diseases, added. "When you know a drug works, you have to let people in the placebo group know so they can take it."
Remedisivir was tried in 2018-19 for ebola. It was pulled 6 months early after 50% using it died. He knew it wasn't safe.
Two drugs reduce risk of death from Ebola
After results from the first 499 participants had been reviewed, the trial’s safety monitors recommended that two drugs—ZMapp and remdesivir—be dropped from the remainder of the trial. These two drugs were much less effective at preventing death.
Overall, about 50% of people who received either Zmapp or remdesivir died during the trial. In contrast, only about 35% of people who received either Mab114 or REGN-EB3 died. Three participants died of side effects thought to be related to treatment—two in the ZMapp group and one in the remdesivir group.

